Factors Influencing Squamous Cell Carcinoma In Situ Recurrence and Implications for Treatment Choice

Andrew J. Matsumoto, Adam R. Schmitt, Logan M. Skelley, Christian Baum

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

BACKGROUND: Numerous treatment modalities have been reported for squamous cell carcinoma in situ (SCCIS). Risk factors for recurrence have not been systematically reviewed.

OBJECTIVE: To systematically review and summarize the data on risk factors that contribute to recurrence of SCCIS.

MATERIALS AND METHODS: A PubMed search was completed using the terms "SCCIS," "Bowen's disease," "Bowen's disease and recurrence," and "Bowen's disease and Mohs." These sources were cross-referenced for the terms "treatment," "management," "therapy," "recurrence," and "margins." Studies were selected on the basis of relevance and applicable treatments.

RESULTS: Immunosuppression was the only variable with a statistically signficant association with progression or recurrence of SCCIS. Although there were no data directly correlating subclinical lateral extension or invasive squamous cell carcinoma within SCCIS with recurrence, evidence supports both of these as common features of SCCIS. Other potential recurrence risk factors for which there are limited supporting data included tumor size, depth of follicular extension, and location.

CONCLUSION: Immunosuppression was the only risk factor associated with increased risk of tumor recurrence. Subclinical tumor extension and occult invasive squamous cell carcinoma are relatively common features that theoretically could increase recurrence risk. These factors should be considered when deciding upon treatment for SCCIS. Further study is required to quantify variables that influence recurrence and to identify optimal treatment options.

Original languageEnglish (US)
Pages (from-to)613-620
Number of pages8
JournalDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Volume44
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Carcinoma in Situ
Squamous Cell Carcinoma
Recurrence
Bowen's Disease
Therapeutics
Immunosuppression
Neoplasms
PubMed

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Factors Influencing Squamous Cell Carcinoma In Situ Recurrence and Implications for Treatment Choice. / Matsumoto, Andrew J.; Schmitt, Adam R.; Skelley, Logan M.; Baum, Christian.

In: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], Vol. 44, No. 5, 01.05.2018, p. 613-620.

Research output: Contribution to journalReview article

@article{4fabb77cf14c40f7a3d2f11eccb94e20,
title = "Factors Influencing Squamous Cell Carcinoma In Situ Recurrence and Implications for Treatment Choice",
abstract = "BACKGROUND: Numerous treatment modalities have been reported for squamous cell carcinoma in situ (SCCIS). Risk factors for recurrence have not been systematically reviewed.OBJECTIVE: To systematically review and summarize the data on risk factors that contribute to recurrence of SCCIS.MATERIALS AND METHODS: A PubMed search was completed using the terms {"}SCCIS,{"} {"}Bowen's disease,{"} {"}Bowen's disease and recurrence,{"} and {"}Bowen's disease and Mohs.{"} These sources were cross-referenced for the terms {"}treatment,{"} {"}management,{"} {"}therapy,{"} {"}recurrence,{"} and {"}margins.{"} Studies were selected on the basis of relevance and applicable treatments.RESULTS: Immunosuppression was the only variable with a statistically signficant association with progression or recurrence of SCCIS. Although there were no data directly correlating subclinical lateral extension or invasive squamous cell carcinoma within SCCIS with recurrence, evidence supports both of these as common features of SCCIS. Other potential recurrence risk factors for which there are limited supporting data included tumor size, depth of follicular extension, and location.CONCLUSION: Immunosuppression was the only risk factor associated with increased risk of tumor recurrence. Subclinical tumor extension and occult invasive squamous cell carcinoma are relatively common features that theoretically could increase recurrence risk. These factors should be considered when deciding upon treatment for SCCIS. Further study is required to quantify variables that influence recurrence and to identify optimal treatment options.",
author = "Matsumoto, {Andrew J.} and Schmitt, {Adam R.} and Skelley, {Logan M.} and Christian Baum",
year = "2018",
month = "5",
day = "1",
doi = "10.1097/DSS.0000000000001400",
language = "English (US)",
volume = "44",
pages = "613--620",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Factors Influencing Squamous Cell Carcinoma In Situ Recurrence and Implications for Treatment Choice

AU - Matsumoto, Andrew J.

AU - Schmitt, Adam R.

AU - Skelley, Logan M.

AU - Baum, Christian

PY - 2018/5/1

Y1 - 2018/5/1

N2 - BACKGROUND: Numerous treatment modalities have been reported for squamous cell carcinoma in situ (SCCIS). Risk factors for recurrence have not been systematically reviewed.OBJECTIVE: To systematically review and summarize the data on risk factors that contribute to recurrence of SCCIS.MATERIALS AND METHODS: A PubMed search was completed using the terms "SCCIS," "Bowen's disease," "Bowen's disease and recurrence," and "Bowen's disease and Mohs." These sources were cross-referenced for the terms "treatment," "management," "therapy," "recurrence," and "margins." Studies were selected on the basis of relevance and applicable treatments.RESULTS: Immunosuppression was the only variable with a statistically signficant association with progression or recurrence of SCCIS. Although there were no data directly correlating subclinical lateral extension or invasive squamous cell carcinoma within SCCIS with recurrence, evidence supports both of these as common features of SCCIS. Other potential recurrence risk factors for which there are limited supporting data included tumor size, depth of follicular extension, and location.CONCLUSION: Immunosuppression was the only risk factor associated with increased risk of tumor recurrence. Subclinical tumor extension and occult invasive squamous cell carcinoma are relatively common features that theoretically could increase recurrence risk. These factors should be considered when deciding upon treatment for SCCIS. Further study is required to quantify variables that influence recurrence and to identify optimal treatment options.

AB - BACKGROUND: Numerous treatment modalities have been reported for squamous cell carcinoma in situ (SCCIS). Risk factors for recurrence have not been systematically reviewed.OBJECTIVE: To systematically review and summarize the data on risk factors that contribute to recurrence of SCCIS.MATERIALS AND METHODS: A PubMed search was completed using the terms "SCCIS," "Bowen's disease," "Bowen's disease and recurrence," and "Bowen's disease and Mohs." These sources were cross-referenced for the terms "treatment," "management," "therapy," "recurrence," and "margins." Studies were selected on the basis of relevance and applicable treatments.RESULTS: Immunosuppression was the only variable with a statistically signficant association with progression or recurrence of SCCIS. Although there were no data directly correlating subclinical lateral extension or invasive squamous cell carcinoma within SCCIS with recurrence, evidence supports both of these as common features of SCCIS. Other potential recurrence risk factors for which there are limited supporting data included tumor size, depth of follicular extension, and location.CONCLUSION: Immunosuppression was the only risk factor associated with increased risk of tumor recurrence. Subclinical tumor extension and occult invasive squamous cell carcinoma are relatively common features that theoretically could increase recurrence risk. These factors should be considered when deciding upon treatment for SCCIS. Further study is required to quantify variables that influence recurrence and to identify optimal treatment options.

UR - http://www.scopus.com/inward/record.url?scp=85048961594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048961594&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000001400

DO - 10.1097/DSS.0000000000001400

M3 - Review article

C2 - 29112529

AN - SCOPUS:85048961594

VL - 44

SP - 613

EP - 620

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 5

ER -